

of the pericardium towards the diaphragm and laterally under the phrenic nerve, instead of in one single bloc, is equally effective for the surgical treatment of myasthenia gravis.

REFERENCES

1. Jaretzki A, Wolff M. Maximal thymectomy for myasthenia gravis. Surgical anatomy and operative technique. *J Thorac Cardiovasc Surg.* 1988;96:711–6.
2. Magee MJ. Optimal surgical approach and extent of resection of the thymus in patients with myasthenia gravis. In: Ferguson MK, editor. *Difficult decisions in thoracic surgery.* 1st ed. Londres: Springer; 2011. p. 433–8.
3. Cheng C, Liu Z, Xu F, Deng Z, Feng H, Lei Y, et al. Clinical outcome of juvenile myasthenia gravis after extended transsternal thymectomy in a Chinese cohort. *Ann Thorac Surg.* 2013;95:1035–42.
4. Prokakis C, Koletsis E, Salakou S, Apostolakis E, Baltayiannis N, Chatzimichalis A, et al. Modified maximal thymectomy for myasthenia gravis: effect of maximal resection on late neurologic outcome and predictors of disease remission. *Ann Thorac Surg.* 2009;88:1638–46.
5. Liu Z, Feng H, Yeung SJ, Zheng Z, Liu W, Ma J, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. *Ann Thorac Surg.* 2011;92:1993–9.
6. Shrager JB. Extended transcervical thymectomy: the ultimate minimally invasive approach. *Ann Thorac Surg.* 2010;89:S2128–34.
7. Meyer DM, Herbert MA, Sobhani NC, Tavakolian P, Duncan A, Bruns M, et al. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. *Ann Thorac Surg.* 2009;87:385–91.
8. Diaz A, Black E, Dunning J. Is thymectomy in non-thymomatous myasthenia gravis of any benefit? *Interact Cardiovasc Thorac Surg.* 2014;18:381–9.
9. Zahi I, Sharif S, Routledge T, Scarci M. Video-assisted thoracoscopic surgery or transternal thymectomy in the treatment of myasthenia gravis? *Interact Cardiovasc Thorac Surg.* 2011;12:40–6.

Francisco J. Vázquez-Roque^{a,*}, María O. Hernández-Olivier^b, Alina Castillo-Vitlloch^a, Deysi Rivero-Valerón^b

^aServicio de Cirugía Cardiovascular, Cardiocentro de Santa Clara, Villa Clara, Cuba

^bServicio de Neurología, Hospital José Luis Miranda de Santa Clara, Villa Clara, Cuba

*Corresponding author.

E-mail address: javier@cardiovc.sld.cu (F.J. Vázquez-Roque).

2173-5077/

© 2015 AEC. Published by Elsevier España, S.L.U. All rights reserved.



Gastric Inflammatory Myofibroblastic Tumour as a Rare Cause of Biliary Duct Obstruction[☆]

Tumor miofibroblástico inflamatorio gástrico como rara causa de obstrucción de la vía biliar

Inflammatory myofibroblastic tumours are a very rare type of benign mesenchymal tumour. Most reported cases affect children and young adults, and these tumours are most often found in the lungs.¹ They can also affect the soft tissue and visceral organs,^{2–6} and cases have been reported of their localisation in the mesentery, omentum, retroperitoneum, extremities, head and neck, genitourinary tract and other organs. Their presence in the stomach, however, is extremely rare. There are fewer than 20 cases of gastric involvement described in the literature, most of which are incidental findings or presentations with intestinal obstruction.^{3,4} Prognosis is unclear, but there have been case reports with recurrence or malignisation with metastasis. For this reason, treatment entails tumour resection; if this is not possible due

to the location or involvement, chemotherapy or radiotherapy treatments are other options.^{3,5}

We report the case of an 88-year-old male patient with a history of arterial hypertension, dyslipidaemia, an episode of acute myocardial infarction (resolved with a coronary stent), chronic atrial fibrillation treated with dicoumarol, and chronic obstructive pulmonary disease; his surgical history included elective cholecystectomy due to symptomatic bile stones at the age of 60. The patient came to the emergency room with oppressive abdominal pain, predominantly in the right hypochondrium and epigastrium, general malaise, nausea and vomiting. On physical examination, the patient was haemodynamically stable, with fever and jaundice of the skin and mucous membranes. The abdomen was soft, painful to

[☆] Please cite this article as: París-Sans M, Domènech-Calvet J, Raga-Carceller E, Sabench-Pereferrer F, del Castillo-Déjardin D. Tumor miofibroblástico inflamatorio gástrico como rara causa de obstrucción de la vía biliar. *Cir Esp.* 2016;94:188–190.



Fig. 1 – (A) CT; (B) polyp in the gastric-pyloric junction. (C) Macroscopic appearance of the tumour.

palpation in the right hypochondrium and epigastrium with an uncertain Murphy sign; there were no palpated masses or enlargements, and no signs of peritoneal irritation. Analytical parameters showed haemoglobin (10.2 g/dL), haematocrit 29.9%, elevated C reactive protein (3 mg/dL) and a pattern of cholestasis (GGT 487 IU/L, alkaline phosphatase 2013 IU/L). Given the clinical suspicion of acute cholangitis, an abdominal ultrasound was ordered, which detected dilatation of the intrahepatic bile duct and proximal common bile duct, with an unclear image of biliary sludge. Having met the criteria for the Charcot triad, the patient was diagnosed with acute cholangitis and was admitted to the general surgery unit for a complete study and administration of endovenous antibiotic treatment.

During hospitalisation, magnetic resonance cholangio-pancreatography demonstrated a slightly dilated bile tract

with no images of choledocholithiasis, which was interpreted as normal given the post-cholecystectomy status. Due to the persistence and intolerance of oral intake, a barium swallow study was ordered. This test showed adequate permeability of the oesophagus, stomach and duodenum, with some irregularities but no clear stenosis, as well as slowed intestinal transit. An associated motor disorder was suspected, and a gastroscopy was performed. This revealed a 2-cm polypoid lesion at the gastroduodenal junction that prolapsed towards the duodenum; biopsies were taken for a pathology study. This test was complemented with an extension study using thoracoabdominal computed tomography, which showed oedematous-looking wall thickening in the region of the bulb and the first-second parts of the duodenum (Fig. 1A). During hospitalisation, the jaundice progressively disappeared and the bilirubinaemia normalised,




Fig. 2 – Histology and immunohistochemistry study; CD34+ and anaplastic lymphoma kinase +.

but an anaemia of 5 g/dL of haemoglobin was detected with a drop of 13 points of haematocrit compared with the initial analyses, and no external evidence of bleeding. After blood transfusion, diagnostic-therapeutic gastroscopy was ordered because of the suspicion of gastrointestinal bleeding secondary to a gastroduodenal polyp. On this occasion, there was a 4-cm polypoid lesion that completely occupied the lumen of the duodenal bulb, extending to the proximal region of the second portion of the duodenum with traces of blood, which appeared to be prolapsed from the prepyloric antrum, forming a false pedicle. The papilla was identified, which presented a discharge of clear bile. Given the size and location, endoscopic resection was not possible, so we proceeded with laparoscopic surgical resection by means of gastroduodenostomy. The polyp was located in the gastric-pyloric region on a prolapsed gastric mucosa, so polypectomy was carried out with a Heineke-Mikulicz pyloroplasty (Fig. 1B). The macroscopic image is shown in Fig. 1C.

The patient progressed correctly, with adequate oral tolerance and disappearance of the abdominal pain. He was discharged from hospital on the 8th day post-op. The pathology report of the polyp reported a mass with morphological and immunohistochemical characteristics compatible with an inflammatory myofibroblastic tumour. Histologically, there was a proliferation of mesenchymal spindle cells mixed with inflammatory cells, predominantly lymphocytes. In the immunohistochemistry study, the tumour cells showed positive immunoreactivity for CD34 but negativity for CD117, desmin, smooth muscle actin and S-100. It was also positive for anaplastic lymphoma kinase (ALK) (Fig. 2).

Inflammatory myofibroblastic tumours are very uncommon and are also known as inflammatory pseudotumors. They are usually asymptomatic or run their course with nonspecific symptoms such as general malaise, abdominal pain, fever or weight loss. They typically affect children and young adults, with a higher prevalence in females (4:1). When adults are affected, it is usually in the 9th decade of life.⁷ The aetiology is unknown, although some support the hypothesis that it could be secondary to an infection, trauma, previous bile duct obstruction or surgical aggression.^{2,3,6} Histopathologically, these tumours are characterised by abundant inflammatory cells, fibroblasts and some collagen deposits.^{2,5} In the stomach, they are extremely rare. For their differentiation from gastrointestinal stromal tumours (GIST), immunohistochemistry should be used for confirmation^{4,6}; even so, it may be negative for anaplastic lymphoma kinase protein.⁸ The evolution of this type of tumours is unpredictable: they can spontaneously regress or grow, become malignant or even metastasise.^{2,3,5,6} For this reason, surgical resection is considered the most effective treatment. In cases where complete resection is not possible or in patients with elevated morbidity, radiotherapy and chemotherapy should be used.^{3,5} The case we present occurred in an older adult patient who began with bile duct obstruction due to extrinsic compression, which triggered a series of symptoms that are unusual for this type of tumours: jaundice, fever, abdominal pain, intolerance to oral intake, and even acute anaemia due to the bleeding of the tumour itself. In conclusion, unpredictable progression of

this type of masses should be considered in order to avoid underdiagnosis or undertreatment. In cases of inflammatory myofibroblastic tumour, treatment should involve complete exeresis when possible; if not, radiotherapy and chemotherapy are required. Post-adjuvant chemotherapy will depend on the baseline conditions of each patient.⁹

REFERENCES

1. Jiang Y, Sun JP, Lu M, Sun Y, Wan L, Zhao H, et al. A rare case with pulmonary and cardiac inflammatory myofibroblastic tumor. *Circulation*. 2015;131:e511–3.
2. Bjelovic M, Micev M, Spica B, Babic T, Gunjic D, Djuric A, et al. Primary inflammatory myofibroblastic tumor of the stomach in an adult woman: a case report and review of the literature. *World J Surg Oncol*. 2013;11:35.
3. Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Başsorgun CI, et al. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. *Case Rep Oncol Med*. 2013;2013:328108.
4. Jain A, Kasana S, Ramrakhiani D, Sharma M. Inflammatory myofibroblastic tumor of the stomach in an adult female—report of a rare case and review of the literature. *Turk J Gastroenterol*. 2012;23:399–405.
5. Mirshemirani A, Khaleghnejad Tabari A, Sadeghian N, Shariati-Torbaghan S, Pourafkari M, Mohajerzadeh L. Abdominal inflammatory myofibroblastic tumor: report of four cases and review literature. *Iran J Pediatr*. 2011;21:543–8.
6. Ribeiro MC, Lopes LR, de Souza Neto JC, Meirelles LR, de Carvalho RB, Andreollo NA. Rare gastric inflammatory myofibroblastic tumor in an adult woman: a case report with review of the literature. *Case Rep Med*. 2012;2012:374070.
7. Savvidou OD, Sakellariou VI, Papakonstantinou O, Skarpidi E, Papagelopoulos PJ. Inflammatory myofibroblastic tumor of the thigh: presentation of a rare case and review of the literature. *Case Rep Orthop*. 2015;2015:814241.
8. Kim DJ, Kim W. Inflammatory myofibroblastic tumor treated with laparoscopic proximal gastrectomy and double-tract anastomosis. *J Gastric Cancer*. 2015;15:64–7.
9. Cianci P, Ambrosi A, Fersini A, Tartaglia N, Lizzi V, Sanguedolce F, et al. Voluminous omental inflammatory myofibroblastic tumor in an elderly man: a case report and literature review. *Case Rep Surg*. 2015;2015:814241.

Marta París-Sans^a, Joan Domènech-Calvet^{ab}, Esther Raga-Carceller^{ab}, Fàtima Sabench-Pereferrer^b, Daniel del Castillo-Déjardin^{ab*}

^aServicio de Cirugía General y del Aparato Digestivo, Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain

^bUnidad de Cirugía, Facultad de Medicina y Ciencias de la Salud, Universitat Rovira i Virgili, Reus, Tarragona, Spain

*Corresponding author.

E-mail address: ddelcastillo@grupsagessa.com
(D. del Castillo-Déjardin).